Gilead Sciences stock gains as analysts turn more positive
Published on 09/02/2026 at 21:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock has recently traded near the upper end of its range, with shares at 129.36 EUR on Tradegate as of September 1, 2026, up 2.68% on the day according to data from Zonebourse.
Analysts highlight valuation and cash flow
New analyst commentary points to a more constructive stance on Gilead Sciences, with one recent overview citing a consensus rating in the moderate buy range and a consensus price target around 158.04 USD, compared with a recent share price of 149.92 USD in the United States as of late August 2026, based on data compiled by MarketBeat.
The same MarketBeat overview notes that Gilead shares recently opened at 149.92 USD on Nasdaq, implying that the consensus fair value estimate of 158.04 USD is about 5.4 percent above that trading level, underscoring a moderate upside view from analysts as of early September 2026.
Stock performance on Tradegate and valuation debates
On the German Tradegate platform, Gilead Sciences is listed under the ticker GIS, with the last recorded price at 129.36 EUR at 22:02:47 on September 1, 2026 and a daily gain of 2.68 percent, as reported by Zonebourse.
In a separate valuation-focused analysis, an investor narrative places Gilead Sciences intrinsic value at around 128.38 USD per share, compared with the same observed market price of 149.92 USD, implying that the stock is about 16.8 percent above that fair value estimate, according to a recent overview on Simply Wall St.
More reports on Gilead Sciences
Further company news, analyst commentary and regulatory filings on Gilead Sciences can be found in the aggregated coverage for this ISIN.
HIV prevention and oncology portfolio in focus
Beyond stock performance, Gilead Sciences recent developments in HIV prevention underscore the strategic importance of its pipeline, with lenacapavir highlighted in a September 2, 2026 communication from the U.S. government as a twice yearly HIV prevention medication supplied to Zambia, reflecting the broader public health impact of the company portfolio.
In oncology, a recent transaction valued at 7.8 billion USD gave Gilead full control of an investigational BCMA directed CAR T therapy called anito cel for relapsed or refractory multiple myeloma, as noted in a September 2, 2026 article on Zacks, and this acquisition expands the company position in cell therapy.
Flagship HIV and oncology products
For many investors, Gilead Sciences is closely associated with its HIV treatment and prevention franchise, including long acting agents such as lenacapavir, which is administered only twice per year and targets high risk populations in global health programs.
At the same time, the oncology business is being built around products such as Trodelvy, a therapy that has drawn attention in Europe and has been cited as a driver of interest in the company oncology franchise, complementing the established antiviral business.
Gilead Sciences stock on Tradegate
As of the Tradegate close on September 1, 2026, Gilead Sciences stock traded at 129.36 EUR with a 2.68 percent gain for the session, under the GIS ticker for the German venue, according to Zonebourse data.
Key data for Gilead Sciences
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Trading venue: Tradegate and Nasdaq
- Price (as of September 1, 2026, 22:02): 129.36 EUR
- Sector / Industry: Biotechnology and pharmaceuticals
- Index membership: S and P 500
